B of A Securities Begins Coverage of iRhythm Technologies with a Buy Rating and Sets Price Target at $200
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 20 2025
0mins
Should l Buy IRTC?
Source: Benzinga
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRTC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRTC
Wall Street analysts forecast IRTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRTC is 222.00 USD with a low forecast of 205.00 USD and a high forecast of 244.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 146.750
Low
205.00
Averages
222.00
High
244.00
Current: 146.750
Low
205.00
Averages
222.00
High
244.00
About IRTC
iRhythm Holdings, Inc. is a digital health care company, which creates solutions that detect, predict, and prevent disease. It designs, develops, and commercializes device-based technology to provide ambulatory cardiac monitoring services. It offers three Zio System options: the Zio Monitor System, the Zio XT System, and the Zio AT System. It offers its Zio ambulatory cardiac monitoring services, including long-term continuous monitoring, short-term continuous monitoring, and mobile cardiac telemetry (MCT) monitoring services, using its Zio Systems. The Zio Monitor System is a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor (the Zio Monitor patch) that records the electric signal from the heart continuously for over 14 days and the Zio ECG Utilization Software (ZEUS) System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation into iRhythm Technologies' Corporate Governance Breaches
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of iRhythm Technologies, Inc. breached their fiduciary duties, potentially impacting corporate governance.
- Legal Relief Options: Long-term shareholders of iRhythm stock may seek corporate governance reforms, fund recovery, or court-approved financial awards, aimed at enhancing transparency and accountability within the company.
- Importance of Participation: Shareholder involvement can improve company policies and oversight mechanisms, thereby increasing shareholder value and enhancing the effectiveness and transparency of management.
- Law Firm Background: Halper Sadeh LLC represents investors globally, focusing on securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors.
See More
iRhythm Technologies Executives Accused of Breaching Fiduciary Duties
- Legal Investigation Launched: Kuehn Law, PLLC is investigating whether executives at iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, as a federal securities lawsuit alleges that executives failed to disclose the true purpose of the Zio AT monitor, potentially harming shareholder interests.
- Market Misleading Actions: Insiders repeatedly touted the Zio AT as an innovative product with growth potential, yet failed to clarify that it was intended for high-risk patients, leading investors to misunderstand its premium pricing and artificially inflate the stock price.
- Shareholder Rights Affected: Due to these misleading actions, iRhythm's stock traded at artificially inflated prices during relevant periods, putting shareholders at risk of investment losses, prompting Kuehn Law to urge shareholders to contact them promptly to protect their rights.
- No Legal Fees: Kuehn Law states that all case costs will be covered by the firm, with no fees charged to investors, encouraging shareholders to get involved to ensure the integrity and fairness of the financial markets.
See More
Kuehn Law Investigates iRhythm Executives for Breach of Fiduciary Duties
- Investigation Background: Kuehn Law, PLLC is investigating whether executives at iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, as a federal securities lawsuit alleges insiders failed to disclose the true purpose of the Zio AT monitor, leading to artificially inflated stock prices.
- Product Misrepresentation: Insiders at iRhythm repeatedly touted the Zio AT as an innovative product with significant growth potential, while it was actually a real-time monitor intended for high-risk patients, which investors viewed favorably due to its premium pricing.
- Stock Price Impact: As a result of these misleading statements, iRhythm's stock traded at artificially inflated prices during relevant periods, potentially causing financial losses for investors, prompting shareholders to contact legal counsel promptly to protect their rights.
- Legal Fee Commitment: Kuehn Law commits to covering all case costs and does not charge its investor clients, encouraging shareholders to get involved to uphold the integrity and fairness of financial markets.
See More
Kuehn Law Investigates iRhythm Executives for Breach of Fiduciary Duties
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, as a federal securities lawsuit alleges insiders failed to disclose the true purpose of the Zio AT monitor, resulting in artificially inflated stock prices during relevant periods.
- Product Misrepresentation: Insiders repeatedly touted the Zio AT as an innovative product poised for growth in the real-time monitoring market for high-risk patients, yet failed to clarify its actual use, potentially misleading investors regarding its premium pricing expectations.
- Shareholder Rights: Due to these misrepresentations, iRhythm's common stock traded at inflated prices, prompting shareholders to contact Kuehn Law immediately to enforce their rights within a limited timeframe.
- Legal Costs: Kuehn Law states that all case costs are covered by the firm, with no charges to investor clients, emphasizing the importance of shareholder participation in maintaining the integrity and fairness of financial markets.
See More
iRhythm Technologies (IRTC) Expects 2025 Revenue to Exceed $740 Million, 2026 Revenue of $870 Million
- 2025 Revenue Outlook: iRhythm anticipates 2025 revenue will exceed the high end of the $740 million guidance, driven by record unit volume in Q4, indicating strong growth potential in the digital health sector.
- 2026 Financial Projections: The company expects revenue of approximately $870 million to $880 million in 2026, reflecting a year-over-year growth of 17% to 18%, surpassing the analyst consensus of $862.68 million, showcasing its competitive strength in the market.
- Market Expansion Strategy: iRhythm plans to deepen penetration in primary care and population health through AI-powered risk stratification partnerships while expanding into adjacent markets like obstructive sleep apnea, highlighting its diversified growth strategy.
- Stock Reaction and Analysis: Despite a 20% drop in iRhythm's stock due to the delay of Zio MCT to 2027, William Blair analysts believe the weakness is overstated and recommend investors seize the buying opportunity, maintaining an Outperform rating.
See More
Vanguard Small-Cap Growth ETF Components: Warby Parker Rises 11.3%
- Highest Volume Component: Plug Power saw a rise of about 2.9% on Tuesday with over 31 million shares traded, indicating strong market interest in its growth potential, which may attract more investors.
- Opendoor Technologies Performance: The company’s stock fell approximately 3.1% with over 25.3 million shares changing hands, reflecting market concerns about its future profitability, potentially impacting its short-term investment appeal.
- Warby Parker's Strong Performance: The stock surged by about 11.3%, making it the best performer on Tuesday, showcasing strong demand and brand recognition in the market, which could drive future growth potential.
- Irhythm Technologies Underperformance: The stock declined by about 8.5%, lagging behind other components in the Vanguard Small-Cap Growth ETF, possibly reflecting market doubts about its business model or financial health, affecting investor confidence.
See More
Investigation into iRhythm Technologies' Corporate Governance Breaches
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of iRhythm Technologies, Inc. breached their fiduciary duties, potentially impacting corporate governance.
- Legal Relief Options: Long-term shareholders of iRhythm stock may seek corporate governance reforms, fund recovery, or court-approved financial awards, aimed at enhancing transparency and accountability within the company.
- Importance of Participation: Shareholder involvement can improve company policies and oversight mechanisms, thereby increasing shareholder value and enhancing the effectiveness and transparency of management.
- Law Firm Background: Halper Sadeh LLC represents investors globally, focusing on securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors.
See More
iRhythm Technologies Executives Accused of Breaching Fiduciary Duties
- Legal Investigation Launched: Kuehn Law, PLLC is investigating whether executives at iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, as a federal securities lawsuit alleges that executives failed to disclose the true purpose of the Zio AT monitor, potentially harming shareholder interests.
- Market Misleading Actions: Insiders repeatedly touted the Zio AT as an innovative product with growth potential, yet failed to clarify that it was intended for high-risk patients, leading investors to misunderstand its premium pricing and artificially inflate the stock price.
- Shareholder Rights Affected: Due to these misleading actions, iRhythm's stock traded at artificially inflated prices during relevant periods, putting shareholders at risk of investment losses, prompting Kuehn Law to urge shareholders to contact them promptly to protect their rights.
- No Legal Fees: Kuehn Law states that all case costs will be covered by the firm, with no fees charged to investors, encouraging shareholders to get involved to ensure the integrity and fairness of the financial markets.
See More
Kuehn Law Investigates iRhythm Executives for Breach of Fiduciary Duties
- Investigation Background: Kuehn Law, PLLC is investigating whether executives at iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, as a federal securities lawsuit alleges insiders failed to disclose the true purpose of the Zio AT monitor, leading to artificially inflated stock prices.
- Product Misrepresentation: Insiders at iRhythm repeatedly touted the Zio AT as an innovative product with significant growth potential, while it was actually a real-time monitor intended for high-risk patients, which investors viewed favorably due to its premium pricing.
- Stock Price Impact: As a result of these misleading statements, iRhythm's stock traded at artificially inflated prices during relevant periods, potentially causing financial losses for investors, prompting shareholders to contact legal counsel promptly to protect their rights.
- Legal Fee Commitment: Kuehn Law commits to covering all case costs and does not charge its investor clients, encouraging shareholders to get involved to uphold the integrity and fairness of financial markets.
See More
Kuehn Law Investigates iRhythm Executives for Breach of Fiduciary Duties
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, as a federal securities lawsuit alleges insiders failed to disclose the true purpose of the Zio AT monitor, resulting in artificially inflated stock prices during relevant periods.
- Product Misrepresentation: Insiders repeatedly touted the Zio AT as an innovative product poised for growth in the real-time monitoring market for high-risk patients, yet failed to clarify its actual use, potentially misleading investors regarding its premium pricing expectations.
- Shareholder Rights: Due to these misrepresentations, iRhythm's common stock traded at inflated prices, prompting shareholders to contact Kuehn Law immediately to enforce their rights within a limited timeframe.
- Legal Costs: Kuehn Law states that all case costs are covered by the firm, with no charges to investor clients, emphasizing the importance of shareholder participation in maintaining the integrity and fairness of financial markets.
See More
iRhythm Technologies (IRTC) Expects 2025 Revenue to Exceed $740 Million, 2026 Revenue of $870 Million
- 2025 Revenue Outlook: iRhythm anticipates 2025 revenue will exceed the high end of the $740 million guidance, driven by record unit volume in Q4, indicating strong growth potential in the digital health sector.
- 2026 Financial Projections: The company expects revenue of approximately $870 million to $880 million in 2026, reflecting a year-over-year growth of 17% to 18%, surpassing the analyst consensus of $862.68 million, showcasing its competitive strength in the market.
- Market Expansion Strategy: iRhythm plans to deepen penetration in primary care and population health through AI-powered risk stratification partnerships while expanding into adjacent markets like obstructive sleep apnea, highlighting its diversified growth strategy.
- Stock Reaction and Analysis: Despite a 20% drop in iRhythm's stock due to the delay of Zio MCT to 2027, William Blair analysts believe the weakness is overstated and recommend investors seize the buying opportunity, maintaining an Outperform rating.
See More
Vanguard Small-Cap Growth ETF Components: Warby Parker Rises 11.3%
- Highest Volume Component: Plug Power saw a rise of about 2.9% on Tuesday with over 31 million shares traded, indicating strong market interest in its growth potential, which may attract more investors.
- Opendoor Technologies Performance: The company’s stock fell approximately 3.1% with over 25.3 million shares changing hands, reflecting market concerns about its future profitability, potentially impacting its short-term investment appeal.
- Warby Parker's Strong Performance: The stock surged by about 11.3%, making it the best performer on Tuesday, showcasing strong demand and brand recognition in the market, which could drive future growth potential.
- Irhythm Technologies Underperformance: The stock declined by about 8.5%, lagging behind other components in the Vanguard Small-Cap Growth ETF, possibly reflecting market doubts about its business model or financial health, affecting investor confidence.
See More
